News

News2020-07-17T11:41:26-04:00
Jul 162020

Halberd Advances the Treatment of COVID-19 Utilizing Laser Technology

July 16th, 2020|Categories: Featured, Investor News|Tags: , , , , , , |

Jackson Center, PA, July 16, 2020 – Halberd Corp. (OTC PINK: "HALB") intends to use laser technology to eradicate the COVID-19 Coronavirus. This patent pending treatment introduces one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., Covid-19 target antigens). This will allow the virus to be seen and located, and allow for eradicating the fluorescent antibody-antigen complex by utilizing an energy burst from a nano-laser, with the removal of the ...

Jul 132020

Halberd Corp – Update July 13, 2020 – Addresses Certain Issues

July 13th, 2020|Categories: Featured, Investor News, News|Tags: , , , |

Jackson Center, PA, July 13, 2020 – Halberd Corp. (OTC PINK: "HALB") today issued a statement to clarify certain items within its charter regarding allowable debt.  There have been inaccurate rumors that have put the company in a negative light.  One of these is that the company intends to take on convertible debt. Nothing could be further from the truth. Halberd’s corporate charter prohibits it from issuing any kind of convertible financial instrument, debt or ...

Jul 72020

COVID-19 Cytokine Storm, Coronavirus’ Deadliest Stage – Halberd’s US Patent Pending Treatment Now Explained!

July 7th, 2020|Categories: Featured, News, Technology|Tags: , , , , , , |

Jackson Center, PA, July 7, 2020 – Halberd Corp. (OTC PINK: "HALB") today explains the second of three (3) COVID -19 (Coronavirus) patent pending treatments - “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients” - which was filed with the U.S. Patent and Trademark Office on April 8, 2020. Halberd Corporation holds the exclusive worldwide license to this technology To combat the patient’s overproduction of inflammatory ...

Jul 12020

Halberd Establishes UK Subsidiary

July 1st, 2020|Categories: Featured, News|Tags: , , |

Jackson Center, PA, July 1, 2020 – Halberd Corporation (OTC-PINK: "HALB") announced the establishment of a subsidiary in the United Kingdom to facilitate access to European research facilities and markets.  The subsidiary is Halberd Corporation UK, Ltd. William A. Hartman, Chairman, President & CEO of Halberd, stated, “This is the first step in our overall plan to expand our reach beyond North America and to establish a global footprint which is necessary given the breadth ...

Jun 292020

Halberd Method for Treating and Curing the COVID-19 Infection Explained

June 29th, 2020|Categories: Featured, News, Technology|Tags: , , , |

Jackson Center, PA, June 29, 2020 – Halberd Corporation (OTC-PINK: "HALB") today unveils the first of three (3) COVID -19 (Coronavirus) patent pending treatment methods -- the first titled, “Method for Treating and Curing Covid-19 Infection” -- filed with the U.S. Patent and Trademark Office on March 16, 2020.  Halberd holds exclusive worldwide license to this technology. The method applicable to any disease entails the extracorporeal (outside the body) treatment of a patient’s blood or ...

Jun 222020

NFL Retired Players Association’s Chief Medical Officer Joins Halberd Corporation to Lead COVID-19 Efforts

June 22nd, 2020|Categories: Featured, News, Technology|Tags: , , , |

Effective Immediately! Jackson Center, PA, June 22, 2020 – Halberd Corporation (OTC Pink: HALB) announced the appointment of Dr. Patricio F. Reyes to the position of Chief Technical Officer effective immediately.  He will report to Halberd’s new Chairman, President and CEO, William A. Hartman and is currently the Chief Medical Officer of the NFL’s Retired Players Association (NFL RPA). Dr. Reyes will head up Halberd Corporation’s efforts in the development of a treatment to eradicate ...

Go to Top